LNA043
Total Payments
$282,192
Transactions
17
Doctors
2
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $6,218 | 3 | 1 |
| 2019 | $19,837 | 5 | 1 |
| 2018 | $204,784 | 6 | 2 |
| 2017 | $51,353 | 3 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $282,192 | 17 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A RANDOMIZED PLACEBO CONTROLLED DOUBLE BLIND FIRST IN HUMAN SINGLE ASCENDING DOSE STUDY OF LNA043 IN PRIMARY OSTEOARTHRITIS PATIENTS SCHEDULED FOR TOTAL KNEE REPLACEMENT | Novartis Pharmaceuticals Corporation | $243,253 | 0 |
| A RANDOMIZED PLACEBO CONTROLLED PATIENT AND INVESTIGATOR BLINDED PROOF OF CONCEPT STUDY INVESTIGATING THE SAFETY TOLERABILITY AND PRELIMINARY EFFICACY OF MULTIPLE INTRA ARTICULAR LNA043 INJECTIONS IN REGENERATING THE ARTICULAR CARTILAGE OF THE KNEE IN PAT | Novartis Pharmaceuticals Corporation | $26,056 | 1 |
| A RANDOMIZED PLACEBO CONTROLLED PATIENT AND INVESTIGATOR BLINDED PROOF OF CONCEPT STUDY INVESTIGATING THE SAFETY TOLERABILITY AND PRELIMINARY EFFICACY OF MULTIPLE INTRA ARTICULAR LNA043 INJECTIONS IN REGENERATING THE ARTICULAR CARTILAGE OF THE KNEE IN PATIENTS WITH ARTICULAR CARTILAGE LESIONS | Novartis Pharmaceuticals Corporation | $7,869 | 0 |
| A RANDOMIZED PLACEBO CONTROLLED PATIENT AND INVESTIGATOR BLINDED PROOF OF CONCEPT STUDY INVESTIGATING THE SAFETY TOLERABILITY AND PRELIMINARY EFFICACY OF MULTIPLE INTRA ARTICULAR LNA043 INJECTIONS IN REGENERATING THE ARTICULAR CARTILAGE OF THE KNEE IN PATIENTS WITH ARTICULAR CARTILAGE LESIONS | NOVARTIS PHARMACEUTICALS CORPORATION | $5,015 | 2 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $282,192
- Total Doctors 2
- Transactions 17
About LNA043
LNA043 is a drug associated with $282,192 in payments to 2 healthcare providers, recorded across 17 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2020. In 2020, $6,218 was paid across 3 transactions to 1 doctors.
The most common payment nature for LNA043 is "Unspecified" ($282,192, 100.0% of total).
LNA043 is associated with 4 research studies, including "A RANDOMIZED PLACEBO CONTROLLED DOUBLE BLIND FIRST IN HUMAN SINGLE ASCENDING DOSE STUDY OF LNA043 IN PRIMARY OSTEOARTHRITIS PATIENTS SCHEDULED FOR TOTAL KNEE REPLACEMENT" ($243,253).